biostudies-literatureBishop MRAuburn University Research Initiative in CancerAuburn University Cellular and Molecular Biosciences Peaks of Excellence Research FellowshipJoy to Life FoundationAURIC Graduate Fellowship ProgramNational Science Foundation Research Excellence for UndergraduatesAmerican Association of Colleges of Pharmacy New Investigator Awarde0220929https://www.ebi.ac.uk/biostudies/studies/S-EPMC6695138biostudies-literatureUnknown14(8)There is a need to investigate and better understand the inherited risk of cancer to ensure that clinical applications provide more accurate assessments and management strategies. Developing research-based next-generation sequencing gene panels that not only target (present-day) clinically actionable susceptibility genes but also genes that currently lack sufficient evidence for risk as well as candidate genes, such as those in DNA repair pathways, can help aid this effort. Therefore, gene panel B.O.P. (Breast, Ovarian, and Prostate) was developed to evaluate the genetic risk of breast, ovarian and/or prostate cancer, and this manuscript serves as an introduction to B.O.P. and highlights its initial analytical validity assessment. B.O.P targets 87 genes that have been suggested, predicted,PloS oneA research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.PMC6695138NSF-EPS-11588621560115Hetzel JHuskey ALWBishop MRMerner NDfalseA research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.There is a need to investigate and better understand the inherited risk of cancer to ensure that clinical applications provide more accurate assessments and management strategies. Developing research-based next-generation sequencing gene panels that not only target (present-day) clinically actionable susceptibility genes but also genes that currently lack sufficient evidence for risk as well as candidate genes, such as those in DNA repair pathways, can help aid this effort. Therefore, gene panel B.O.P. (Breast, Ovarian, and Prostate) was developed to evaluate the genetic risk of breast, ovarian and/or prostate cancer, and this manuscript serves as an introduction to B.O.P. and highlights its initial analytical validity assessment. B.O.P targets 87 genes that have been suggested, predicted,2019-01-01T00:00:00Z20192026-04-08T05:51:20.097Z2019-08-21T07:03:11ZS-EPMC66951383141562710.1371/journal.pone.0220929